miRecule
Daniel Jacobs is the Founder and Managing Director of Pathway Bioventures, an early-stage life sciences fund established in March 2018, which focuses on investing in innovative therapeutics, medical devices, and diagnostics to enhance human health. In addition, Daniel serves as a Board Observer for miRecule, Inc., a biotechnology firm dedicated to developing antibody-RNA conjugate therapeutics for various diseases, and as an Entrepreneur in Residence at Yale Ventures since September 2022. Daniel's prior experience includes a postdoctoral fellowship at the Dan L. Duncan Comprehensive Cancer Center at Baylor College of Medicine, where research focused on the genomics of familial brain cancer, and clinical research at the Robert H. Lurie Comprehensive Cancer Center during 2008-2010. Daniel holds a PhD in Genetic and Molecular Epidemiology from Yale University, an MPH in Chronic Disease Epidemiology from Yale School of Public Health, and a BA in Economics and Business Institutions from Northwestern University.
This person is not in any teams
This person is not in any offices
miRecule
MiRecule is an early-stage biotechnology company that focuses on developing microRNA-based therapeutics. It features a genomic-based drug development platform that integrates genomic sequencing, expression, and prognostic data from cancer patients.The company was founded in 2016 and headquartered in Gaithersburg, United States.